NVCR

Novocure Ltd

Add to Watchlist

Advanced Chart

11.080

-0.05(-0.449%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

11.080

Open

11.080

VWAP

11.08

Vol

481.00

Mkt Cap

1.24B

Low

11.080

Amount

5.33K

EV/EBITDA(TTM)

Total Shares

107.61M

990.20M

EV/OCF(TTM)

P/S(TTM)

1.94

NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

161.34M

+4.1%

-0.420

+35.48%

160.19M

-0.66%

-0.491

-19.44%

158.81M

+2.4%

-0.423

+51.02%

Estimates Revision

The market is revising Upward the revenue expectations for NovoCure Limited (NVCR) for FY2025, with the revenue forecasts being adjusted by 1.05% over the past three months. During the same period, the stock price has changed by -40.33%.

Revenue Estimates for FY2025

Revise Upward

+1.05%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-4.15%

In Past 3 Month

Stock Price

Go Down

-40.33%

In Past 3 Month

7 Analyst Rating

139.17% Upside

Wall Street analysts forecast NVCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVCR is 26.50 USD with a low forecast of 11.00 USD and a high forecast of 38.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

3 Hold

0 Sell

Moderate Buy

139.17% Upside

Current: 11.080

Low

11.00

Averages

26.50

High

38.00

139.17% Upside

Current: 11.080

Low

11.00

Averages

26.50

High

38.00

Wells Fargo

Larry Biegelsen

Overweight -> Equal Weight

downgrade

$40

2025-07-24

Reason

Wells Fargo

Larry Biegelsen

Price Target

$40

2025-07-24

downgrade

Overweight -> Equal Weight

Reason

Wells Fargo analyst Larry Biegelsen downgraded Novocure to Equal Weight from Overweight with a price target of $14.50, down from $40.

Wells Fargo

Overweight -> Equal Weight

downgrade

$40

2025-07-24

Reason

Wells Fargo

Price Target

$40

2025-07-24

downgrade

Overweight -> Equal Weight

Reason

Wells Fargo downgraded Novocure to Equal Weight from Overweight with a price target of $14.50, down from $40. The company reported \"disappointing\" Q2 results, including softer glioblastoma scripts outside the U.S. and a slow ramp in lung cancer, the analyst tells investors in a research note. Meanwhile, the pact from yhr PANOVA-3 and METIS studies are more than 12 months out, the firm adds. Wells is positive on Optune longer term but does not catalysts to drive share outperformance over the next year.

Ladenburg

Kevin Degeeter

initiated

$30

2025-07-08

Reason

Ladenburg

Kevin Degeeter

Price Target

$30

2025-07-08

initiated

Reason

Ladenburg analyst Kevin Degeeter initiated coverage of Novocure with a Buy rating and $30 price target.

Ladenburg

NULL -> Buy

initiated

$30

2025-07-08

Reason

Ladenburg

Price Target

$30

2025-07-08

initiated

NULL -> Buy

Reason

As previously reported, Ladenburg initiated coverage of Novocure with a Buy rating and $30 price target. The firm cites a positive outlook for Optune Gio to retain \"healthy market share\" in glioblastoma, a path to profitability based on uptake of Optune Lua in treatment of second-line non small cell lung cancer and evidence supporting Tumor Treating Fields as a platform technology for various solid tumors.

Wells Fargo

Overweight

maintain

$40

2025-06-02

Reason

Wells Fargo

Price Target

$40

2025-06-02

maintain

Overweight

Reason

Wells Fargo is "encouraged" by Novocure's ASCO presentation, saying the data and panel were generally positive on PANOVA-3 and tumor treating fields for pancreatic cancer. The firm believes the key PANOVA-3 endpoints were generally positive. Wells sees the data as supporting approval and adoption in pancreatic cancer. It models a late 2026 U.S. launch with further launches to follow in 2027, and material revenue starting in 2028. Wells keeps an Overweight rating on Novocure with a $40 price target. The stock in midday trading is down 7% to $17.73.

Piper Sandler

Jason Bednar

Buy

Maintains

$42 → $34

2025-04-23

Reason

Piper Sandler

Jason Bednar

Price Target

$42 → $34

2025-04-23

Maintains

Buy

Reason

Piper Sandler lowered the firm's price target on Novocure to $34 from $42 and keeps an Overweight rating on the shares ahead of quarterly results. The firm notes that policy and broad economic uncertainty has seemingly created opportunities for investors to do value shopping. Piper thinks an in-line quarter for GBM is on tap, particularly as performance ex-France has been fairly mediocre for several quarters running. Ramping of NSCLC - both Rx and active patients - may prove to be the bigger influencer on stock performance, and the firm believes investor skepticism on success in NSCLC makes for a positive setup heading into this week's result.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Novocure Ltd (NVCR.O) is -6.34, compared to its 5-year average forward P/E of 15.96. For a more detailed relative valuation and DCF analysis to assess Novocure Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

15.96

Current PE

-6.34

Overvalued PE

460.41

Undervalued PE

-428.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-109.54

Current EV/EBITDA

-6.84

Overvalued EV/EBITDA

239.41

Undervalued EV/EBITDA

-458.49

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

13.08

Current PS

2.00

Overvalued PS

22.99

Undervalued PS

3.17